These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 37027349)

  • 1. Vaccination coverage and breakthrough infections of COVID-19 during the second wave among staff of selected medical institutions in India.
    Rahi M; Yadav CP; Ahmad SS; Nitika ; Das P; Sharma S; Baharia RK; Bhattacharya D; Deshmukh P; Dhatrak A; Dogra S; Eapen A; Goel P; Faizi N; Khan SA; Kochar SK; Kochar A; Kumar A; Mundra A; Narang R; Narain K; Pandey K; Pati S; Raghav P; Ranjha R; Shah S; Singh K; Singh PK; Singh RK; Kuttiatt VS; Soni R; Sreehari U; Malhotra S; Sharma A
    PLOS Glob Public Health; 2023; 3(4):e0000946. PubMed ID: 37027349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Media Reporting Relating to COVID-19 Vaccination as a Driver of Vaccine Hesitancy Prior to the Second Wave of the COVID-19 Pandemic in India: A Content Analysis of Newspaper and Digital Media Reports.
    Basu S; Sharma H
    Cureus; 2023 Mar; 15(3):e36750. PubMed ID: 37123709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of prior vaccination with Covishield
    Abhilash KPP; Mathiyalagan P; Krishnaraj VRK; Selvan S; Kanagarajan R; Reddy NP; Rajendiran N; Hazra D; Gunasekaran K; Moorthy M; Jasmine S; Davis JP; George T; George K; Varghese GM; Rupali P; Barney Isaac TJ; Gupta R; Pichamuthu K; Joy M; Jayaseelan L; Mathews P; Peter JV
    Vaccine; 2022 Mar; 40(13):2107-2113. PubMed ID: 35168837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
    Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
    Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study.
    Keri VC; Arunan B; Kodan P; Soneja M; Nischal N; Varadarajan A; Didwania A; R L B; Aggarwal A; Jorwal P; Kumar A; Ray A; Sethi P; Meena VP; Khanna P; Singh AK; Aggarwal R; Soni KD; Goyal A; Das A; Trikha A; Wig N
    Ther Adv Vaccines Immunother; 2022; 10():25151355221115009. PubMed ID: 35966176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
    Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
    Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
    Behera P; Singh AK; Subba SH; Mc A; Sahu DP; Chandanshive PD; Pradhan SK; Parida SP; Mishra A; Patro BK; Batmanabane G
    Hum Vaccin Immunother; 2022 Dec; 18(1):2034456. PubMed ID: 35321625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors.
    Parameswaran A; Apsingi S; Eachempati KK; Dannana CS; Jagathkar G; Iyer M; Aribandi H
    Infection; 2022 Aug; 50(4):889-895. PubMed ID: 35129788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections: A single metro-based testing network experience.
    Strickler SS; Esper A; Wells L; Wood A; Frediani JK; Nehl E; Waggoner JJ; Rebolledo PA; Levy JM; Figueroa J; Ramachandra T; Lam W; Martin GS
    Front Med (Lausanne); 2022; 9():1031083. PubMed ID: 36507539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
    Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
    Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers.
    Kale P; Gupta E; Bihari C; Patel N; Rooge S; Pandey A; Bajpai M; Khillan V; Chattopadhyay P; Devi P; Maurya R; Jha N; Mehta P; Kumar M; Sharma P; Saifi S; Swaminathan A; Alam S; Uppili B; Faruq M; Agrawal A; Pandey R; Sarin SK
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai.
    Shetty A; Chatterjee G; Rajpal S; Srivastava T; Gardi N; Mirgh S; Gokarn A; Punatar S; Shetty N; Joshi A; Nair S; Murthy V; Khattry N; Tembhare P; Dikshit R; Chaturvedi P; More A; Kamtalwar S; Chavan P; Bhat V; Patil A; Dhumal S; Bhat P; Subramanian P; Gujral S; Badwe R; Patkar N; Gupta S
    Int J Clin Pract; 2022; 2022():2449068. PubMed ID: 35685574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
    Arora G; Taneja J; Bhardwaj P; Goyal S; Naidu K; Yadav SK; Saluja D; Jetly S
    J Med Virol; 2022 Jul; 94(7):3147-3154. PubMed ID: 35261064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era.
    Shah SA; Robertson C; Rudan I; Murray JL; McCowan C; Grange Z; Buelo A; Sullivan C; Simpson CR; Ritchie LD; Sheikh A
    J Glob Health; 2022; 12():05008. PubMed ID: 35356660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-Epidemiological Profile of Breakthrough COVID-19 Infection among Vaccinated Beneficiaries from a COVID-19 Vaccination Centre in Bihar, India.
    Singh CM; Singh PK; Naik BN; Pandey S; Nirala SK; Singh PK
    Ethiop J Health Sci; 2022 Jan; 32(1):15-26. PubMed ID: 35250213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Reinfections Among Fully Vaccinated and Unvaccinated University Athletes-15 States, January-November 2021.
    Good MK; Czarnik M; Harmon KG; Aukerman D; O'Neal CS; Day C; Goerl K; Sifre K; Fink S; Riggs MA
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S236-S242. PubMed ID: 35771661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.